% alzhub.org library filter
% Source: https://alzhub.org/research?author=Salloway+S&score_min=70
% 15 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{salloway2025-40390253,
  author  = {Salloway, S. and Pain, A. and Lee, E. and Papka, M. and Ferguson, M. B. and Wang, H. and Hu, H. and Lu, M. and others},
  title   = {{TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2025},
  doi     = {10.1002/alz.70293},
  pmid    = {40390253},
  url     = {https://doi.org/10.1002/alz.70293}
}

@article{salloway2014-24450891,
  author  = {Salloway, S. and Sperling, R. and Fox, N. C. and Blennow, K. and Klunk, W. and Raskind, M. and Sabbagh, M. and Honig, L. S. and others},
  title   = {{Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease}},
  journal = {The New England journal of medicine},
  year    = {2014},
  doi     = {10.1056/nejmoa1304839},
  pmid    = {24450891},
  url     = {https://doi.org/10.1056/nejmoa1304839}
}

@article{salloway2022-34807243,
  author  = {Salloway, S. and Chalkias, S. and Barkhof, F. and Burkett, P. and Barakos, J. and Purcell, D. and Suhy, J. and Forrestal, F. and others},
  title   = {{Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease}},
  journal = {JAMA neurology},
  year    = {2022},
  doi     = {10.1001/jamaneurol.2021.4161},
  pmid    = {34807243},
  url     = {https://doi.org/10.1001/jamaneurol.2021.4161}
}

@article{salloway2021-34155411,
  author  = {Salloway, S. and Farlow, M. and McDade, E. and Clifford, D. B. and Wang, G. and Llibre-Guerra, J. J. and Hitchcock, J. M. and Mills, S. L. and others},
  title   = {{A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease}},
  journal = {Nature medicine},
  year    = {2021},
  doi     = {10.1038/s41591-021-01369-8},
  pmid    = {34155411},
  url     = {https://doi.org/10.1038/s41591-021-01369-8}
}

@article{bateman2023-37966285,
  author  = {Bateman, R. J. and Smith, J. and Donohue, M. C. and Delmar, P. and Abbas, R. and Salloway, S. and Wojtowicz, J. and Blennow, K. and others},
  title   = {{Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease}},
  journal = {The New England journal of medicine},
  year    = {2023},
  doi     = {10.1056/nejmoa2304430},
  pmid    = {37966285},
  url     = {https://doi.org/10.1056/nejmoa2304430}
}

@article{salloway2025-39556389,
  author  = {Salloway, S. and Wojtowicz, J. and Voyle, N. and Lane, C. A. and Klein, G. and Lyons, M. and Rossomanno, S. and Mazzo, F. and others},
  title   = {{Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease}},
  journal = {JAMA neurology},
  year    = {2025},
  doi     = {10.1001/jamaneurol.2024.3937},
  pmid    = {39556389},
  url     = {https://doi.org/10.1001/jamaneurol.2024.3937}
}

@article{black2003-12970516,
  author  = {Black, S. and Román, G. C. and Geldmacher, D. S. and Salloway, S. and Hecker, J. and Burns, A. and Perdomo, C. and Kumar, D. and others},
  title   = {{Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial}},
  journal = {Stroke},
  year    = {2003},
  doi     = {10.1161/01.str.0000091396.95360.e1},
  pmid    = {12970516},
  url     = {https://doi.org/10.1161/01.str.0000091396.95360.e1}
}

@article{salloway2018-30129411,
  author  = {Salloway, S. and Marshall, G. A. and Lu, M. and Brashear, H. R.},
  title   = {{Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study}},
  journal = {Current Alzheimer research},
  year    = {2018},
  doi     = {10.2174/1567205015666180821114813},
  pmid    = {30129411},
  url     = {https://doi.org/10.2174/1567205015666180821114813}
}

@article{sims2023-9857475c,
  author  = {Sims, JR. and Zimmer, J. A. and Evans, C. D. and Lu, M. and Ardayfio, P. and Sparks, J. and Wessels, A. M. and Shcherbinin, S. and Wang, H. and Monkul Nery, E. S. and Collins, E. C. and Solomon, P. and Salloway, S. and Apostolova, L. G. and Hansson, O. and Ritchie, C. and Brooks, D. A. and Mintun, M. and Skovronsky, D. M. and {TRAILBLAZER-ALZ 2 Investigators}},
  title   = {{Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial}},
  journal = {JAMA},
  year    = {2023},
  pmid    = {37459141}
}

@article{salloway2009-19923550,
  author  = {Salloway, S. and Sperling, R. and Gilman, S. and Fox, N. C. and Blennow, K. and Raskind, M. and Sabbagh, M. and Honig, L. S. and others},
  title   = {{A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease}},
  journal = {Neurology},
  year    = {2009},
  doi     = {10.1212/wnl.0b013e3181c67808},
  pmid    = {19923550},
  url     = {https://doi.org/10.1212/wnl.0b013e3181c67808}
}

@article{coric2012-22892585,
  author  = {Coric, V. and van Dyck, C. H. and Salloway, S. and Andreasen, N. and Brody, M. and Richter, R. W. and Soininen, H. and Thein, S. and others},
  title   = {{Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease}},
  journal = {Archives of neurology},
  year    = {2012},
  doi     = {10.1001/archneurol.2012.2194},
  pmid    = {22892585},
  url     = {https://doi.org/10.1001/archneurol.2012.2194}
}

@article{salloway2004-15326237,
  author  = {Salloway, S. and Ferris, S. and Kluger, A. and Goldman, R. and Griesing, T. and Kumar, D. and Richardson, S. and {Donepezil 401 Study Group}},
  title   = {{Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial}},
  journal = {Neurology},
  year    = {2004},
  doi     = {10.1212/01.wnl.0000134664.80320.92},
  pmid    = {15326237},
  url     = {https://doi.org/10.1212/01.wnl.0000134664.80320.92}
}

@article{coric2015-26414022,
  author  = {Coric, V. and Salloway, S. and van Dyck, C. H. and Dubois, B. and Andreasen, N. and Brody, M. and Curtis, C. and Soininen, H. and others},
  title   = {{Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2015},
  doi     = {10.1001/jamaneurol.2015.0607},
  pmid    = {26414022},
  url     = {https://doi.org/10.1001/jamaneurol.2015.0607}
}

@article{pontecorvo2019-31009046,
  author  = {Pontecorvo, M. J. and Devous, M. D. and Kennedy, I. and Navitsky, M. and Lu, M. and Galante, N. and Salloway, S. and Doraiswamy, P. M. and others},
  title   = {{A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia}},
  journal = {Brain : a journal of neurology},
  year    = {2019},
  doi     = {10.1093/brain/awz090},
  pmid    = {31009046},
  url     = {https://doi.org/10.1093/brain/awz090}
}

@article{dichgans2008-18296124,
  author  = {Dichgans, M. and Markus, H. S. and Salloway, S. and Verkkoniemi, A. and Moline, M. and Wang, Q. and Posner, H. and Chabriat, H. S.},
  title   = {{Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL}},
  journal = {The Lancet. Neurology},
  year    = {2008},
  doi     = {10.1016/s1474-4422(08)70046-2},
  pmid    = {18296124},
  url     = {https://doi.org/10.1016/s1474-4422(08)70046-2}
}